Correction to: Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1934
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Correction to: Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder ; volume:36 ; number:11 ; day:3 ; month:10 ; year:2022 ; pages:1239 ; date:11.2022
CNS drugs ; 36, Heft 11 (3.10.2022), 1239, 11.2022
- Urheber
-
Nie, Tina
Blair, Hannah A.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40263-022-00957-7
- URN
-
urn:nbn:de:101:1-2023012621103428827975
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Nie, Tina
- Blair, Hannah A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Correction to: Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder
Emerging treatments for neuromyelitis optica spectrum disorder
Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder
Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate
Unveiling the retinal secrets of neuromyelitis optica spectrum disorder
Health utilities and costs for neuromyelitis optica spectrum disorder
Cerebrospinal fluid mitochondrial DNA in neuromyelitis optica spectrum disorder
CD22 blockade exacerbates neuroinflammation in Neuromyelitis optica spectrum disorder
Functional disability of neuromyelitis optica spectrum disorder in Brazil
Neuromyelitis optica and neuromyelitis optica spectrum disorder: Natural history and long-term outcome, an Indian experience
Neuromyelitis Optica Spectrum Disorder Coinciding with Spinocerebellar Ataxia Type 31
Correction to: Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder
Emerging treatments for neuromyelitis optica spectrum disorder
Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder
Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate
Unveiling the retinal secrets of neuromyelitis optica spectrum disorder
Health utilities and costs for neuromyelitis optica spectrum disorder
Cerebrospinal fluid mitochondrial DNA in neuromyelitis optica spectrum disorder
CD22 blockade exacerbates neuroinflammation in Neuromyelitis optica spectrum disorder
Functional disability of neuromyelitis optica spectrum disorder in Brazil
Neuromyelitis optica and neuromyelitis optica spectrum disorder: Natural history and long-term outcome, an Indian experience
Neuromyelitis Optica Spectrum Disorder Coinciding with Spinocerebellar Ataxia Type 31
Correction to: Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder
Emerging treatments for neuromyelitis optica spectrum disorder
Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder
Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate
Unveiling the retinal secrets of neuromyelitis optica spectrum disorder
Health utilities and costs for neuromyelitis optica spectrum disorder
Cerebrospinal fluid mitochondrial DNA in neuromyelitis optica spectrum disorder
CD22 blockade exacerbates neuroinflammation in Neuromyelitis optica spectrum disorder
Functional disability of neuromyelitis optica spectrum disorder in Brazil
Neuromyelitis optica and neuromyelitis optica spectrum disorder: Natural history and long-term outcome, an Indian experience